Literature DB >> 11441928

The Swedish Council on Technology Assessment in Health Care (SBU) report on Cancer Chemotherapy--Project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation.

P Nygren1, B Glimelius.   

Abstract

The major objective of the Swedish Council on Technology Assessment in Health Care (SBU in its Swedish abbreviation) Chemotherapy Project was to review and assess the evidence, as presented in the scientific literature, for the use of chemotherapy in some major tumour types. The purpose of this assessment was to establish the current evidence-based role of this treatment modality in various settings in these tumour types. The basis for the assessment was the perspective of the conditions in Swedish health care and a prospective survey within the project detailed the use of chemotherapy in two health-care regions in Sweden. This formed the basis for an assessment of the use of chemotherapy in relation to scientific evidence. The project focused on standard cytotoxic chemotherapy, whether delivered at conventional doses or at higher doses with various supportive actions, and did not address the role of other emerging approaches that could broadly be included under the heading chemotherapy, e.g. drugs with anti-angiogenesis and anti-metastatic properties or chemopreventive drugs. In this introduction, the project objectives, working process, key definitions and general aspects on cancer trial methodology and interpretation are presented and discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11441928

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

Review 1.  Modelling and simulation in the development and use of anti-cancer agents: an underused tool?

Authors:  Ferdinand Rombout; Leon Aarons; Mats Karlsson; Anthony Man; France Mentré; Peter Nygren; Amy Racine; Hans Schaefer; Jean-Louis Steimer; Iñaki Troconiz; Achiel van Peer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-12       Impact factor: 2.745

Review 2.  Benefit-risk assessment of irinotecan in advanced colorectal cancer.

Authors:  Bengt Glimelius
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience.

Authors:  James D Cox; Sergio A Giralt; Mary L Veazie; Jaffer A Ajani; Janet M Bruner; Ka Wah Chan; Walter N Hittelman; Kelly K Hunt; Revathy B Iyer; Daniel D Karp; Deborah A Kuban; Scott M Lippman; Issam I Raad; Miguel A Rodriguez-Bigas; Leonard A Zwelling; Maurie Markman
Journal:  Oncology       Date:  2009-07-01       Impact factor: 2.935

4.  Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells.

Authors:  Shijie Zhang; Lei Wang; Hongchun Liu; Guoqiang Zhao; Liang Ming
Journal:  Diagn Pathol       Date:  2014-03-20       Impact factor: 2.644

5.  Mistletoe Preparation Iscador: Are there Methodological Concerns with Respect to Controlled Clinical Trials?

Authors:  Renatus Ziegler
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-04       Impact factor: 2.629

Review 6.  South Asian Medicinal Compounds as Modulators of Resistance to Chemotherapy and Radiotherapy.

Authors:  N Rajendra Prasad; Ganesan Muthusamy; Mohana Shanmugam; Suresh V Ambudkar
Journal:  Cancers (Basel)       Date:  2016-03-05       Impact factor: 6.639

7.  Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapy-a retrospective analysis of a register-based patient cohort.

Authors:  Isabella Ekheden; Fereshte Ebrahim; Halla Ólafsdóttir; Pauline Raaschou; Björn Wettermark; Roger Henriksson; Weimin Ye
Journal:  Eur J Clin Pharmacol       Date:  2020-05-05       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.